眾生藥業(002317.SZ):眾生睿創一類創新藥RAY1225注射液用於2型糖尿病患者的II期臨牀試驗完成首例受試者入組
格隆匯2月27日丨眾生藥業(002317.SZ)公佈,公司控股子公司廣東眾生睿創生物科技有限公司(簡稱“眾生睿創”)自主研發的一類創新多肽藥物RAY1225注射液,已於2024年2月同步啟動用於2型糖尿病及超重/肥胖患者的兩項II期臨牀試驗,並於近日完成2型糖尿病II期臨牀試驗的首例受試者入組。
在組長單位PI的指導下,眾生睿創於近日完成2型糖尿病II期臨牀試驗的首例受試者入組。眾生睿創將繼續按照相關要求高質量、加速度、科學規範地推進RAY1225注射液的兩項II期臨牀試驗。GLP-1類藥物是近年來受到普遍關注的一類代謝性疾病治療藥物,可用於降糖、減肥等治療領域,並在非酒精性脂肪性肝炎(NASH)、阿爾茨海默症、心衰等多個疾病領域展示出潛力。據米內網中國公立醫療機構終端競爭格局數據庫顯示,2022年GLP-1類產品實現銷售49.70億元,同比增長117.90%;2023年上半年實現銷售36.78億元,同比增長74.72%,國內GLP-1類藥物正實現高速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.